助手标题  
全文文献 工具书 数字 学术定义 翻译助手 学术趋势 更多
查询帮助
意见反馈
   免疫诱导 在 泌尿科学 分类中 的翻译结果: 查询用时:0.243秒
图标索引 在分类学科中查询
所有学科
泌尿科学
消化系统疾病
中药学
水产和渔业
基础医学
外科学
更多类别查询

图标索引 历史查询
 

免疫诱导
相关语句
  immunity induction
    Immunity induction therapy was performed with Zenapax one hour before preoperation,Immunosuppressive drugs consisted of FK506,MMC and corticosteroid.
    术前1小时予赛尼哌(Zenapax)行免疫诱导治疗。 术后免疫抑制治疗采用普乐可复(FK506)、骁悉(MMC)、激素联合应用。
短句来源
    CONCLUSION: Zenapax used for immunity induction of renal transplantation can prevent and reduce the occurrence of acute reject reaction,it has safety and good tolerance.
    结论:赛尼哌用于肾移植的免疫诱导治疗,可以预防和减少急性排斥反应的发生,安全性和耐受性好。
短句来源
  “免疫诱导”译为未确定词的双语例句
    Anti-CD25 Ab (Zenapax) induction therapy in sensitized recipients of renal transplantation
    抗CD25抗体在致敏受者肾脏移植免疫诱导治疗中的临床观察
短句来源
    The dosages of ALG (induced immune-inhibited therapy) in the recipients with CMV infection or no CMV infection were ( 14.1± 1.32) and ( 13.2± 0.92) respectively with the difference being not significant (P> 0.05).
    CMV感染和无CMV感染的肾移植受者ALG免疫诱导治疗疗程分别为 ( 4 .7± 1.3 2 )d、( 4 .4± 0 .92 )d ,使用剂量分别为 ( 14 .1± 1.3 2 )支、( 13 .2±0 .92 )支 ,差异无显著性 (P >0 .0 5 )。
短句来源
    Methods 214 recipients were treated with methylprednisolone (MP), antilymphocyte globulin (ALG) as induced immune-inhibited therapy after renal transplantation.
    方法 2 14例肾移植受者术后给予甲泼尼龙 (MP)、抗淋巴细胞球蛋白 (ALG)静脉滴注作为免疫诱导治疗。
短句来源
    Immunodepressive therapy with low doses of ALG may not increase the incidence of CMV infection.
    术后短期的ALG免疫诱导治疗可能不增加CMV感染发生率 ;
短句来源
    The humanized mAb Daclizumab(Zenapax) was given to recipient as immuned induction treatment at preoperative one hour and postoperative 14 days respectively. Baseline immunosuppressive drugs consisted of FK506,mycophenolate mofetil(MMF) and corticosteroid.
    术前 1h及术后 14d给予Daclizumab行免疫诱导治疗 ,术后免疫抑制治疗包括FK5 0 6、霉酚酸酯 (MMF)及激素。
短句来源
更多       
查询“免疫诱导”译词为用户自定义的双语例句

    我想查看译文中含有:的双语例句
例句
为了更好的帮助您理解掌握查询词或其译词在地道英语中的实际用法,我们为您准备了出自英文原文的大量英语例句,供您参考。
  immunity induction
For one thing the antigen caused immunity induction and for another the tolerance formation represent acentral phaenomenon which includes in any case the entire organism.
      


Objectives To investigate the incidence of cytomegalovirus (CMV) infection and the effects of immunodepressive on CMV infection in renal allograft recipients.Methods 214 recipients were treated with methylprednisolone (MP), antilymphocyte globulin (ALG) as induced immune-inhibited therapy after renal transplantation. The baseline immune-inhibited therapy was cyclosporine A, prednisone plus immurane. Methylprednisolone was prescribed to treat acute reject reactions(AR). If MP showed no effect, ALG or OKT3...

Objectives To investigate the incidence of cytomegalovirus (CMV) infection and the effects of immunodepressive on CMV infection in renal allograft recipients.Methods 214 recipients were treated with methylprednisolone (MP), antilymphocyte globulin (ALG) as induced immune-inhibited therapy after renal transplantation. The baseline immune-inhibited therapy was cyclosporine A, prednisone plus immurane. Methylprednisolone was prescribed to treat acute reject reactions(AR). If MP showed no effect, ALG or OKT3 was prescribed. CMV-PP65 antigen was detected by using immunocytochemical methods at weekly intervals during the first 3 months after transplantation.Results 126 out of 214 recipients ( 61.7%) developed CMV infection. The antigen-positive cells were detected at the day ( 25.4± 14.7) with the average antigen-positive cells being ( 9.2± 7.9) per 50 000 leukocytes. The incidence of AR in the renal transplant recipients before CMV infection was 42.3% (52/126),and was obviously higher than in those without CMV infection ( 20.5%, P< 0.01). Among the 52 recipients with AR reaction, 23 and 16 of them were treated with ALG or OKT3 respectively, significantly more than that of the recipients with no CMV infection to treat acute reject reaction with ALG or OKT3 (P< 0.05). The dosages of ALG (induced immune-inhibited therapy) in the recipients with CMV infection or no CMV infection were ( 14.1± 1.32) and ( 13.2± 0.92) respectively with the difference being not significant (P> 0.05).Conclusions The incidence of CMV infection in renal allograft recipients is high. Immunodepressive therapy with low doses of ALG may not increase the incidence of CMV infection. The therapy with ALG or OKT3 after acute reject reaction may be relative with CMV infection in renal allograft recipients.

目的 探讨肾移植受者巨细胞病毒 (CMV)感染率及免疫抑制剂对其的影响。方法 2 14例肾移植受者术后给予甲泼尼龙 (MP)、抗淋巴细胞球蛋白 (ALG)静脉滴注作为免疫诱导治疗。基础免疫抑制剂治疗为环孢素A +泼尼松 +硫唑嘌呤。急性排斥反应时给予MP冲击治疗 ,无效时给予ALG或OKT3治疗。采用免疫细胞化学LSAB法测定外周血白细胞CMV PP65抗原。结果 CMV感染率为 61.7% ( 12 6/ 2 14 ) ,初次检出CMV PP65抗原的时间为术后 ( 2 5 .4± 14 .7)d ,平均抗原阳性细胞数为每 5 0 0 0 0白细胞 ( 9.2± 7.9)个。CMV感染的肾移植受者在感染前急性排斥反应率为4 2 .3 % ( 5 2 / 12 6) ,明显高于无CMV感染受者的 2 0 .5 % (P <0 .0 1) ;使用ALG或OKT3治疗例数分别为 2 3、15例 ,也高于无CMV感染的受者 (P <0 .0 5 )。CMV感染和无CMV感染的肾移植受者ALG免疫诱导治疗疗程分别为 ( 4 .7± 1.3 2 )d、( 4 .4± 0 .92 )d ,使用剂量...

目的 探讨肾移植受者巨细胞病毒 (CMV)感染率及免疫抑制剂对其的影响。方法 2 14例肾移植受者术后给予甲泼尼龙 (MP)、抗淋巴细胞球蛋白 (ALG)静脉滴注作为免疫诱导治疗。基础免疫抑制剂治疗为环孢素A +泼尼松 +硫唑嘌呤。急性排斥反应时给予MP冲击治疗 ,无效时给予ALG或OKT3治疗。采用免疫细胞化学LSAB法测定外周血白细胞CMV PP65抗原。结果 CMV感染率为 61.7% ( 12 6/ 2 14 ) ,初次检出CMV PP65抗原的时间为术后 ( 2 5 .4± 14 .7)d ,平均抗原阳性细胞数为每 5 0 0 0 0白细胞 ( 9.2± 7.9)个。CMV感染的肾移植受者在感染前急性排斥反应率为4 2 .3 % ( 5 2 / 12 6) ,明显高于无CMV感染受者的 2 0 .5 % (P <0 .0 1) ;使用ALG或OKT3治疗例数分别为 2 3、15例 ,也高于无CMV感染的受者 (P <0 .0 5 )。CMV感染和无CMV感染的肾移植受者ALG免疫诱导治疗疗程分别为 ( 4 .7± 1.3 2 )d、( 4 .4± 0 .92 )d ,使用剂量分别为 ( 14 .1± 1.3 2 )支、( 13 .2±0 .92 )支 ,差异无显著性 (P >0 .0 5 )。结论 肾移植术后CMV感染率高 ;术后短期的ALG免疫诱导治疗可能不增加CMV感染发生率 ;急性排斥反应发生后免疫抑制剂尤其是ALG或OKT3的使用与术后CMV感染密切相关。

Purpose To investigate the surgical techniques,clinical experiences and therapeutic effects of combined liver kidney transplantation(CLKT) Methods Combined liver kidney transplantation was performed on one patient with liver cirrhosis and hepatic encephalopathy of hepatitis B and uremia of chronic nephritis complicated with milticapsular liver,bilateral kidney and portal vein stenosis. ABO blood type incompatible but matched (group O to B)cadave ric allografts were used in the CLKT. Liver and kidney...

Purpose To investigate the surgical techniques,clinical experiences and therapeutic effects of combined liver kidney transplantation(CLKT) Methods Combined liver kidney transplantation was performed on one patient with liver cirrhosis and hepatic encephalopathy of hepatitis B and uremia of chronic nephritis complicated with milticapsular liver,bilateral kidney and portal vein stenosis. ABO blood type incompatible but matched (group O to B)cadave ric allografts were used in the CLKT. Liver and kidney transplantation was carried out by using orthotopic and ordinary methods respectively.The humanized mAb Daclizumab(Zenapax) was given to recipient as immuned induction treatment at preoperative one hour and postoperative 14 days respectively.Baseline immunosuppressive drugs consisted of FK506,mycophenolate mofetil(MMF) and corticosteroid.Lamividine was used on day 60 preoperation and day 7 postoperation respectively.In the meantime hepatitis B immunoglobin (HBIg) was injected musclely. Results The complications included acute and chronic rejection has not been taken placed since the transplantation day.Both transplant organs had rapidly normal functions postoperation,without primary nonfunction of liver graft happened.The patients has been survived for 10 months with normal life quality. Conclusions Skilled operation techniques,comprehensive monitoring perioperatively and correct management are all major factors for success.ABO blood type incompatible but matched(group O to B) cadaveric CLKT can be performed safely.The induction treatment of Zenapax and baseline immunosuppression consisted of FK506,MMF and corticosteroid are effective and safe.Combination therapies of Lamividine and HBIg to prevent HBV recurrence may be more effective.

目的 总结并探讨肝肾联合移植的手术技术、临床治疗经验及疗效。方法 患者因多囊肝并门脉主干先天性狭窄畸形、双侧多囊肾及乙型肝炎后肝硬化、反复发作性肝性脑病 ,并伴有慢性肾功能衰竭而施行一期肝肾联合移植。供、受体血型不一致但相匹配 (O型 -B型 )。肝移植采用经典的原位肝移植技术 ,肾移植采用常规方法。术前 1h及术后 14d给予Daclizumab行免疫诱导治疗 ,术后免疫抑制治疗包括FK5 0 6、霉酚酸酯 (MMF)及激素。分别于术前 60d和术后 7d开始服用抗乙肝病毒药 (贺普丁、Laminvudine) ,并肌注乙肝免疫球蛋白 (HBIg)。结果 受者术后无手术并发症发生 ,移植肝、肾功能恢复良好 ,乙型肝炎再感染被控制 ,现已术后近 10个月。结论 完善的手术技巧、围手术期的严密监测及并发症的及时正确处理等是肝肾联合移植成功的重要条件 ;ABO血型不一致但符合输血原则的供受体间进行肝或肝肾联合移植可以取得良好的临床治疗效果 ;Daclizumab的免疫诱导加以FK5 0 6为主的三联治疗免疫抑制效果良好 ;联合应用Laminvudine和HBIg预防乙肝复发效果更好

Objective To explore the possible causes of transplant renal artery stenosis (TRAS) in cadaveric transplant recipients. Method We retrospectively analyzed multiple factors that may contribute to TRAS (including the patients' age, presence of diabetes, cold ischemic time, acute rejection episode, cytomegalovirus infection, serum cholesterol, LDL cholesterol, pre-operative dialysis, number of donor renal arteries, which side of donor kidney, type of surgical anastomosis, different protocols of inductive and...

Objective To explore the possible causes of transplant renal artery stenosis (TRAS) in cadaveric transplant recipients. Method We retrospectively analyzed multiple factors that may contribute to TRAS (including the patients' age, presence of diabetes, cold ischemic time, acute rejection episode, cytomegalovirus infection, serum cholesterol, LDL cholesterol, pre-operative dialysis, number of donor renal arteries, which side of donor kidney, type of surgical anastomosis, different protocols of inductive and maintenance drug therapy) in 18 recipients with transplant renal artery stenosis after cadveric renal transplantation from Jan. 2000 to Dec. 2001 in comparison with another 566 non-TRAS recipients who underwent the transplan- tation during the same period. Results There was a higher incidence of acute rejection in the TRAS group than non-TRAS group (66.67% vs5.48%, P<0.01), and no significant difference was noted between TRAS and non-TRAS cases in terms of the pre-operative dialysis, presence of diabetes, cold ischemic time, number of donor renal arteries, whith side of donor kidney, type of surgical anastomosis, different protocols of inductive and maintenance drug therapy, cytomegalovirus infections and serum and LDL cholesterols. Conclusion The occurrence of TRAS in cadaveric allografts is associated with acute graft rejection episode, suggesting the importance of the treatment of acute graft rejection in the prevention of TRAS.

目的探讨尸体肾移植术后移植肾动脉狭窄(TRAS)的可能发病原因。方法对尸体肾移植术后18例TRAS患者与未发生TRAS的566受者有可能影响TRAS发生的多个因素进行统计分析。结果(1)TRAS患者的肾移植术后急性排斥反应发生率显著高于非TRAS者(66.67% vs5.48% , P<0.01);(2)发生与未发生TRAS的受者在术前透析方式、糖尿病发病、供肾冷缺血时间、供肾动脉数、供肾侧、供肾动脉吻合方式、术后免疫诱导用药、术后口服免疫维持治疗、术后巨细胞病毒感染以及发病时血脂等诸方面均无显著差异。结论肾移植术后TRAS的发生与移植术后急性排斥反应的发生有密切关系。

 
<< 更多相关文摘    
图标索引 相关查询

 


 
CNKI小工具
在英文学术搜索中查有关免疫诱导的内容
在知识搜索中查有关免疫诱导的内容
在数字搜索中查有关免疫诱导的内容
在概念知识元中查有关免疫诱导的内容
在学术趋势中查有关免疫诱导的内容
 
 

CNKI主页设CNKI翻译助手为主页 | 收藏CNKI翻译助手 | 广告服务 | 英文学术搜索
版权图标  2008 CNKI-中国知网
京ICP证040431号 互联网出版许可证 新出网证(京)字008号
北京市公安局海淀分局 备案号:110 1081725
版权图标 2008中国知网(cnki) 中国学术期刊(光盘版)电子杂志社